title: Effects of heart rate reduction with ivabradine on exercise-induced myocardial ischemia and stunning.
abstract: We investigated the effects of the selective bradycardic agent ivabradine, an I(f) channel inhibitor, on exercise-induced ischemia and resulting myocardial stunning. Seven dogs were chronically instrumented to measure left ventricular (LV) wall thickening (Wth), aortic pressure and coronary blood flow (CBFv) (Doppler). Circumflex coronary artery stenosis was set up to suppress the increase in CBFv during a 10 min treadmill exercise. During exercise under saline, LVWth in the ischemic zone was depressed (-70 +/- 4%) and a prolonged myocardial stunning was subsequently observed. Infusion of ivabradine started before exercise significantly reduced heart rate (HR) at rest (-22 +/- 7%), during exercise (-33 +/- 4%) and throughout the recovery period (-21 +/- 2%). By reducing HR during exercise, ivabradine simultaneously improved LVWth compared with saline (14 +/- 1% versus 7 +/- 1%, respectively) and subendocardial perfusion (microspheres). This anti-ischemic effect was subsequently responsible for a strong decrease in the intensity and severity of myocardial stunning. All these beneficial effects were abolished when HR reduction during exercise was suppressed by atrial pacing. Interestingly, when ivabradine infusion was started after exercise, LVWth was still significantly enhanced and myocardial stunning strongly attenuated. This direct effect of ivabradine on the stunned myocardium disappeared when HR reduction was suppressed by atrial pacing at rest. In conclusion, this study demonstrates that ivabradine exerts an anti-ischemic effect that is responsible for subsequent protection against myocardial stunning. Furthermore, administration of ivabradine after the ischemic insult still improves LVWth of the stunned myocardium.
authors.affiliation: Laboratoire de Pharmacologie, Institut National de la Santé et de la Recherche Médicale, Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre, France.
authors.forename: X
authors.initials: X
authors.lastname: Monnet
authors.forename: B
authors.initials: B
authors.lastname: Ghaleh
authors.forename: P
authors.initials: P
authors.lastname: Colin
authors.forename: O P
authors.initials: OP
authors.lastname: de Curzon
authors.forename: J F
authors.initials: JF
authors.lastname: Giudicelli
authors.forename: A
authors.initials: A
authors.lastname: Berdeaux
mesh_terms: D000818:Animals; D001552:Benzazepines / Q000494:pharmacology*; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004285:Dogs; D006339:Heart Rate / Q000187:drug effects*; D000077550:Ivabradine; D009200:Myocardial Contraction / Q000187:drug effects; D017202:Myocardial Ischemia / Q000503:physiopathology*; D017682:Myocardial Stunning / Q000503:physiopathology*; D010805:Physical Conditioning, Animal; D012039:Regional Blood Flow / Q000187:drug effects
chemical_list: D001552:Benzazepines; D002316:Cardiotonic Agents; D000077550:Ivabradine